TABLE 4.

The primary and secondary outcomes of low-dose and high-dose aspirin.

Outcome	Aspirin<300 mg/d	Model	HR [95% CI] a	p-value
30-day mortality, n (%)
YES	379 (10.4)	Crude	2.51 [2.07, 3.06]	<0.001
NO	3280 (89.6)	Adjusted*	1.57 [1.27, 1.95]	<0.001
90-day mortality, n (%)
YES	562 (15.4)	Crude	2.11 [1.78, 2.51]	<0.001
NO	3097 (84.6)	Adjusted*	1.38 [1.14, 1.67]	0.001
180-day mortality, n (%)
YES	676 (18.5)	Crude	2.19 [1.87, 2.56]	<0.001
NO	2983 (81.5)	Adjusted*	1.44 [1.21, 1.71]	<0.001
			OR[95% CI] a
Transfusion, n (%)
YES	1708 (46.7)	Crude	0.57 [0.48, 0.69]	<0.001
NO	1951 (53.3)	Adjusted*	1.52 [1.17, 1.97]	0.002
ICH, n (%)
YES	18 (0.5)	Crude	3.93 [1.79, 8.25]	<0.001
NO	3641 (99.5)	Adjusted*	2.27 [0.74, 6.92]	0.146
GI Bleeding, n (%)
YES	36 (1.0)	Crude	1.77 [0.83, 3.46]	0.111
NO	3623 (99.0)	Adjusted*	1.37 [0.59, 2.99]	0.441

GI Bleeding, gastrointestinal bleeding; ICH: intracranial hemorrhage. HR, hazard ratio; OR, odds ratio; CI, confidence interval; *Adjusted: gender, age, race, hemoglobin, WBC, platelets, anion gap, bicarbonate, bun, chloride, creatinine, sodium, potassium, heart rate, mean blood pressure, respiratory rate, temperature, spo2, myocardial infarct, congestive heart failure, cerebrovascular disease, mild liver disease, severe liver disease, hypertension, diabetes mellitus, chronic kidney disease, glucose, sepsis, paraplegia, malignant cancer, dementia, Charlson comorbidity index, SOFA, SAPSII, GCS scores, invasive mechanical ventilation, renal replacement therapy; AKI stage, first care unit, vasopressor use.

^a Aspirin<300 mg/d as reference.